FiercePharmaOriginal article
{"a":[{"_":"Johnson & Johnson scores 1st FDA label expansion for Imaavy","$":{"href":"/pharma/johnson-johnson-scores-its-first-fda-label-expansion-imaavy","hreflang":"en"}}]}
RegulatoryapprovedImaavyPositive
AI Analysis
Summary
Johnson & Johnson received FDA approval for a label expansion of Imaavy to treat warm autoimmune hemolytic anemia, a rare disorder that destroys red blood cells, 16 months after the drug's initial FDA approval.
Outcome Details
FDA label expansion approved for warm autoimmune hemolytic anemia
Importance:6/10
Sentiment:
0.70
FDA approvallabel expansionmonoclonal antibodyrare diseaseautoimmune
Related Companies
Read the original article
Published by FiercePharma on August 25, 2026 7:42 AM